University of California San Diego .
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chung, Sue
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
406
Europe, Canada, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
04/29

Download Options